The proportion of patients who gained 15 letters in the intravitreal aflibercept and sham groups was 60.2 % vs 22.1 % at week 24 ( patients discontinued before week 24 were considered nonresponders ; P < .0001 ) , 60.2 % vs 32.4 % at week 52 ( last observation carried forward , P < .001 ) , and 57.3 % vs 29.4 % at week 76 ( last observation carried forward ; P < .001 ) .